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Pat1 RNA-binding proteins, enriched in processing
bodies (P bodies), are key players in cytoplasmic 50
to 30 mRNA decay, activating decapping of mRNA
in complex with the Lsm1-7 heptamer. Using co-
immunoprecipitation and immunofluorescence ap-
proaches coupled with RNAi, we provide evidence
for a nuclear complex of Pat1b with the Lsm2-8 hep-
tamer, which binds to the spliceosomal U6 small
nuclear RNA (snRNA). Furthermore, we establish
the set of interactions connecting Pat1b/Lsm2-8/U6
snRNA/SART3 and additional U4/U6.U5 tri-small nu-
clear ribonucleoprotein particle (tri-snRNP) compo-
nents in Cajal bodies, the site of snRNP biogenesis.
RNA sequencing following Pat1b depletion revealed
the preferential upregulation of mRNAs normally
found in P bodies and enriched in 30 UTR AU-rich el-
ements. Changes in >180 alternative splicing events
were also observed, characterized by skipping of
regulated exons with weak donor sites. Our data
demonstrate the dual role of a decapping enhancer
in pre-mRNA processing as well as in mRNA decay
via distinct nuclear and cytoplasmic Lsm complexes.
INTRODUCTION
Pat1 RNA-binding proteins (DNA topoisomerase 2-associated
protein; PATL1) are conserved from fungi to humans. Deletion
of Pat1 results in a thermosensitive slow growth phenotype in
Saccharomyces cerevisiae (Bonnerot et al., 2000; Wyers et al.,
2000), dwarfism in Arabidopsis thaliana (Roux et al., 2015), and
embryonic lethality in Caenorhabditis elegans and Drosophila
melanogaster (Kamath et al., 2003; Pradhan et al., 2012).
Moreover, homozygous PATL1 knockout mice are sub-viable
(Dickinson et al., 2016). Such incomplete penetrance is oftenCell R
This is an open access article undassociated with paralog proteins. Indeed, while yeast and inver-
tebrates possess one paralog, vertebrates have two: Pat1a
(PATL2), which is expressed in oocytes, and Pat1b (PATL1),
which is expressed in embryos and the soma (reviewed in Mar-
nef and Standart, 2010).
Sequence conservation within and between Pat1 paralogs is
largely confined to their C-terminal half portions, with the N-ter-
minal half predicted to be largely disordered (Jonas and Izaur-
ralde, 2013; Marnef and Standart, 2010). The C-terminal half re-
gion comprises the so-called Mid domain and the PatC domain,
the only structurally solved domain that forms an a-a superhelix
(Braun et al., 2010; Sharif andConti, 2013;Wu et al., 2014). Pat1b
and invertebrate orthologs function in cytoplasmicmRNA decay,
as first shown in yeast, where its deletion stabilized reporter
mRNA in a capped and deadenylated form (Bonnerot et al.,
2000; Bouveret et al., 2000; Tharun et al., 2000). This led to its
classification as an enhancer of decapping, as deadenylation
precedes decapping in the 50-to-30 mRNA decay pathway. In
Drosophila and mammalian tissue cells, its mRNA decay func-
tion has been largely evidenced by the tether function assay
(Braun et al., 2010; Haas et al., 2010; Kamenska et al., 2014;
Marnef and Standart, 2010; Ozgur et al., 2010; Totaro et al.,
2011). Pat1 proteins also mediate translational repression in
yeast and Xenopus oocytes (Coller and Parker, 2005; Marnef
et al., 2010).
The multiple conserved roles of Pat1 proteins in mRNA
silencing at the level of turnover and translation were affirmed
in investigations of its binding partners. In yeast, the best-char-
acterized interaction of Pat1p is with the Lsm1-7 complex.
This cytoplasmic heptamer complexed to Pat1p tends to bind
U-rich tracts at or near the 30 end of oligoadenylated rather
than polyadenylated mRNA (Chowdhury et al., 2007; Mitchell
et al., 2013), protecting the last 20–30 nt of the transcript (He
and Parker, 2001). These RNA-binding properties require both
the Lsm1-7 ring and Pat1p (Chowdhury et al., 2014). Moreover,
Lsm1-7 subunits and Pat1p are required for normal rates of de-
capping in vivo (Bouveret et al., 2000; Tharun et al., 2000). The
Lsm1-7/Pat1 complex is thus considered as a conserved playereports 20, 1187–1200, August 1, 2017 ª 2017 The Author(s). 1187
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in mRNA decay, linking deadenylation to decapping. Subse-
quent structural studies revealed direct interactions between
yeast Lsm2 and Lsm3 subunits and the PatC domain (Sharif
and Conti, 2013; Wu et al., 2014). Indeed, the PatC domain,
and its interaction with Lsm2/3, is required for decapping in
yeast and Drosophila (Braun et al., 2010; Wu et al., 2014).
Additional Pat1-binding proteins include DDX6 (Dhh1p), a
DEAD box RNA helicase implicated in translational repression
and decapping (reviewed in Ayache et al., 2015), and other
decapping co-activators, including Edc3 and Edc4. Consistent
with its role in mRNA decay, Pat1 also co-immunoprecipitates
the CCR4-NOT deadenylase complex, Dcp1/2 decapping
enzyme, and Xrn1 exonuclease (Braun et al., 2010; Haas et al.,
2010; Ozgur et al., 2010).
Pat1 proteins and these interacting proteins are found
concentrated in cytoplasmic foci, or processing bodies
(P bodies), which are implicated in the control of mRNA storage
and decay and contain translational repressors, decay enzymes,
and mRNA (Decker and Parker, 2012; Eulalio et al., 2007). For
example, in glucose-starved yeast, Pat1p is enriched in P bodies
(Sheth and Parker, 2003; Teixeira and Parker, 2007), and human
Pat1b is a component of P bodies present constitutively in
mammalian cell lines and is required for their efficient formation
(Ayache et al., 2015; Marnef et al., 2010; Ozgur et al., 2010).
At steady state, Pat1 proteins are predominantly cytoplasmic,
but early clues in yeast that Pat1 could be nucleocytoplasmic
proteins were more recently confirmed in mammalian cells (Mar-
nef et al., 2012; Teixeira and Parker, 2007). Human Pat1b is
confined to nuclei in the presence of the nuclear export inhibitor
leptomycin B or when its nuclear export sequence (NES) is
mutated, indicating that its export is mediated by Crm1 (Marnef
et al., 2012) and hinting at a hitherto unidentified role of Pat1b in
the nucleus. Here, we provide evidence for a nuclear Pat1b/
Lsm2-8 complex enriched in Cajal bodies, in addition to the
well-studied cytoplasmic Pat1b/Lsm1-7 complex in P bodies.
This study considerably extends our previous observation of
the nucleocytoplasmic shuttling nature of human Pat1b and
identifies an unanticipated role of Pat1b in alternative splicing.
RESULTS
The Pat1b Interactome Includes Predicted Cytoplasmic
Partners and Tri-snRNP Components
The study was initiated by identifying Pat1b protein partners,
based on the reasoning that these interacting factors could offer
clues to its functions in the cytoplasm and nucleus. FLAG-Pat1b
or FLAG-GFP control plasmids were expressed in HEK293 cells.
The resulting total cell lysates were incubated with M2-Sephar-
ose beads, and bound proteins were eluted with FLAG peptide
and subsequently analyzed by mass spectrometry (Figure 1).
A total of 166 proteins, represented by two or more unique
peptides, interacted specifically with Pat1b, but not the control
GFP. Figure 1A lists the top 27 interacting proteins, ranked by
score (full details are given in Table S1). Gene Ontology (GO)
analysis of these proteins revealed a highly significant associa-
tion with RNA processing and splicing process terms (Figure 1B).
Accordingly, many of the interacting factors could be classified
into functional subgroups, including mRNA decay/translational1188 Cell Reports 20, 1187–1200, August 1, 2017repression, splicing, and RNA-binding protein categories, dis-
cussed further below (Figure 1C). Additional groups of co-factors
included the methylosome, phosphatases/kinases, and protea-
some subunits. The methylosome components are of interest
as symmetric arginine methylation of Sm proteins and Lsm4 in-
fluence interactions with survival motor neuron protein (SMN)
and P-body formation (Arribas-Layton et al., 2016; Brahms
et al., 2001). Pat1b is a phosphoprotein, although the sites and
consequences of phosphorylation are not fully characterized.
In yeast, protein kinase A (PKA) phosphorylation of Pat1p disas-
sembles P bodies and reduces long-term survival of stationary
phase cells (Ramachandran et al., 2011), while serines 179 and
184 of human Pat1b are potential mTOR sites (Kang et al., 2013).
Focusing on the RNA-binding protein categories, FLAG-Pat1b
immunoprecipitated its predicted cytoplasmic partners DDX6,
Lsm proteins, CNOT1, Xrn1, and the decapping activator
Edc4, reflecting its role in mRNA decay. Unexpectedly, the
Pat1b immunoprecipitate also contained almost the entire set
of tri-small nuclear ribonucleoprotein particle (tri-snRNP) factors,
including SART3 (Prp24 in yeast), Prp31, snRNP200/Brr2, Prp4,
and Prp3 (Figures 1A, 1C, and 1D; Table S1). The spliceosome
assembles on pre-mRNA to define the boundaries between
exons and introns using >150 proteins and U1, U2, U4, U5,
and U6 snRNP complexes. Three of these join as a pre-formed
unit called the tri-snRNP (U4/U6.U5), which recycles after each
splicing event (reviewed Chen and Moore, 2014). SART3 (squa-
mous cell carcinoma antigen recognized by T cells) promotes U4
and U6 small nuclear RNA (snRNA) annealing to form the U4/U6
di-snRNP, which then associates with U5 snRNP, mediated by
Prp31 and Prp6 interactions to form the mature tri-snRNP. U6
snRNA uniquely interacts with Lsm2-8, rather than Sm proteins,
that are common to U1, U2, U4, and U5 snRNP. The uridine-rich
30 end of U6 snRNA binds the inner face of the Lsm2-8 heptamer
(Zhou et al., 2014) and its telestem region, Prp24/SART3 (Monte-
mayor et al., 2014). Prp3 and Prp4 interact with each other in
U4/U6 di-snRNP, which also includes NHP2L1 and PPIH, while
snRNP200, Prp8, and EFTUD2 are U5 snRNP proteins (Fig-
ure 1D; Agafonov et al., 2016; Bell et al., 2002; Nguyen et al.,
2016; Wahl et al., 2009).
An alternative immunoprecipitation approach was used,
based on GFP-Trap pull-down of YFP-Pat1b, also in HEK293
cells. Here too, we noted high retention of DDX6, CNOT1,
Xrn1, Lsm proteins, and decapping factors, including Dcp1a,
Dcp2, Edc4, and Edc3. Strikingly, DDX6 and SART3 were again
among the top three interacting proteins (based on unique
peptide number). In addition to SART3, YFP-Pat1b also bound
Prp8, snRNP200, Prp3, Prp4, and NHP2L1 (Table S2).
Thus, two independent methods of purifying Pat1b-binding
proteins demonstrated its known interactions not only with
DDX6 and the 50-30 mRNA decay machinery but also, unexpect-
edly and specifically, with most of the tri-snRNP components.
Verification of Pat1b/tri-snRNP Interactions
FLAG-Pat1b immunoprecipitation of selected protein and RNA
tri-snRNP components was validated by western and northern
blotting and qPCR (Figure 2). To identify regions of Pat1b neces-
sary for co-purification, we tested Pat1b N-terminal and C-termi-
nal constructs (Figure 2A). We also examined the effects of a
Figure 1. Pat1b Interactome Analysis
(A) Mass spectrometry results of the top 27 proteins specifically co-immunoprecipitating with FLAG-Pat1b, ranked by MudPit score.
(B) GO analysis of the high-confidence Pat1b-interacting proteins.
(C) Schematic cartoon showing major complexes of Pat1b-interacting proteins.
(D) Schematic cartoon of tri-snRNP protein and RNA constituents, adapted from Wahl et al. (2009). Peptides corresponding to boxed proteins co-immuno-
precipitate with Pat1b.
See also Tables S1 and S2.
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Figure 2. Pat1b Interacts with Tri-snRNP Protein and RNA Components
(A) Schematic cartoon of FLAG-Pat1b constructs, including the N-terminal, C-terminal, and T552E/A constructs.
(B) HEK293 cells were transiently transfected with FLAG-GFP and FLAG-Pat1b plasmids, and lysates were immunoprecipitated with M2 Sepharose. The full-
length FLAG-Pat1b lysate was also treated with RNase A. Bound proteins were analyzed by western blotting with the indicated antibodies.
(C) FLAG-tagged GFP, Pat1b, and SART3 immunoprecipitation was carried out as above. Northern blot analysis of RNA from bound fractions, with indicated
snRNA probes.
(D) Comparison of RNA bound to FLAG-tagged proteins determined by northern blot analysis and qRT-PCR, quantitated as ratio of immunoprecipitated (IP) RNA
to input RNA.
See also Figures S1–S4.
1190 Cell Reports 20, 1187–1200, August 1, 2017
Pat1b mutation, T522E, on protein and RNA binding. The muta-
tion was hypothesized to impact Pat1b interactions on the basis
of two criteria. First, themutation introduces a negative charge in
the basic patch formed by a set of ten arginine and lysine resi-
dues at the very N terminus of the PatC domain, shown to bind
RNA (Braun et al., 2010). Second, T522 lies within the a1A helix,
which binds Lsm3 and Lsm2, but it faces away from them (Fig-
ure S1; Sharif and Conti, 2013; Wu et al., 2014). In some exper-
iments, we also used the charge-neutral T522A mutation.
DDX6 and Lsm1/2 interacted with full-length Pat1b efficiently
and specifically, and this binding was not affected by RNase
treatment, as shown previously (Braun et al., 2010; Ozgur
et al., 2010). We also demonstrated an interaction with Lsm8,
the specific component of the nuclear Lsm2-8 heptamer ring
(Figure 2B, lanes 1–3). In line with prior studies, DDX6 binds
the N-terminal and Lsm1/2, as well as Lsm8, the C-terminal re-
gion of Pat1b (Figure 2B, lanes 6 and 7).
As shown in Figure 2B, we next confirmed the efficient interac-
tion of FLAG-Pat1b with SART3. We further verified that FLAG-
SART3 immunoprecipitates Pat1b in a reciprocal pull-down
experiment and provides evidence of the association between
endogenous SART3 and Pat1b proteins (Figure S2). FLAG-
Pat1b also interacted with Prp31, and both SART3 and Prp31
bind the C-terminal rather than N-terminal region of Pat1b (Fig-
ure 2B, lanes 6 and 7). However, the interaction between
Pat1b and SART3 required both the Mid and PatC domains,
whereas the PatC domain was sufficient for Prp31 binding to
SART3 (Figure S3). Interestingly, efficient Lsm co-immunopre-
cipitation with Pat1b also required the two C-terminal domains
(Braun et al., 2010). Moreover, while SART3 failed to bind
Pat1b in the presence of RNase, Prp31 interacts with Pat1b in
an RNA-independent manner (Figure 2B, lanes 2 and 3), together
highlighting their distinct modes of binding.
We then examined the interaction of Pat1bwith snRNA. FLAG-
GFP, FLAG-Pat1b, and FLAG-SART3 transiently expressed
proteins were immunopurified as described in Experimental Pro-
cedures, and retained RNA was extracted and submitted to
northern blotting or qRT-PCR (Figures 2C and 2D). Confirming
the presence of the tri-snRNP in Pat1b complexes, these ap-
proaches showed that Pat1b co-purifies with U4 and U6 snRNA,
but not U1 snRNA, and it did so via its C-terminal region (Figures
2C, 2D, and S4). As expected, SART3 also preferentially co-
immunoprecipitated U4 and U6 snRNA (Figures 2C and 2D).
The T522E, but not the T522A mutation, in Pat1b abolished its
interaction with SART3, although neither affected DDX6 binding
(Figure 2B, lanes 4 and 5). Similarly, the T-E mutation, but not
the T-A mutation, reduced U4/U6 snRNA co-precipitation with
Pat1b (Figures 2C, 2D, and S4). The effects of the T-E mutation
seemingly mirrored RNase treatment of immunoprecipitated
Pat1b (i.e., specific loss of SART3 binding as well as that of
U4/U6 snRNA), suggesting a possible direct interaction between
Pat1b and snRNA; however, we could not detect any interaction
between recombinant Pat1bC-ter and U4/U6 snRNA in vitro
(data not shown). Indeed, an alternative outcome of the mutation
was indicated when monitoring Lsm interactions. As shown in
Figure 2B, the T-E mutation disrupted Pat1b-Lsm8 binding, did
not affect its interaction with Lsm1, and partly reduced its bind-
ing to Lsm2. The simplest interpretation of these observations isthat the T-E mutation in Pat1b abrogates Lsm2-8 and thus also
U6 snRNA/SART3 binding, but not the interactions with Lsm1-7.
Collectively, these data show that the C-terminal region of
Pat1b binds to SART3, Prp31, Lsm proteins, and U4/U6 snRNA,
with a different mode of interaction for SART3/snRNA versus
Prp31 and for the nuclear versus cytoplasmic Lsm complex.
Pat1b’s Interaction with SART3 and U6 snRNA Is
Mediated by Lsm2-8
To explore further the link between Pat1b and SART3, we used
small interfering RNAs (siRNAs) to reduce SART3 and Lsm1/
2/8 protein levels in cells co-expressing FLAG-GFP or FLAG-
Pat1b plasmids and performed FLAG immunoprecipitation as
before, followed by western blot and qRT-PCR analysis (Fig-
ure 3). Prp31 and DDX6 binding to Pat1b was unaffected by
any depletion. Overall levels of SART3 were unaffected by siRNA
treatments, although depleting Lsm2 unexpectedly reduced the
levels of Lsm1 and Lsm8 as well as Lsm2, but such a co-reduc-
tion was not seen with Lsm1 or Lsm8 depletion (Figure 3, input
lanes; also see Figure 6E). A similar effect was observed in
HeLa cells (Figure S6). Strikingly, Pat1b co-precipitation of
SART3 was prevented when Lsm2 or Lsm8 was depleted (Fig-
ure 3A, lanes 5 and 6). In contrast, reduced Lsm1 levels did
not affect and may even enhance SART3 binding to Pat1b (Fig-
ure 3A, lane 4). In line with the idea that SART3/Pat1b binding is
mediated by Lsm2/8, qRT-PCR of RNAs co-purifying with FLAG-
Pat1b also showed Lsm2/8-specific effects. Lsm1 depletion did
not significantly affect U6 snRNA binding by Pat1b, whereas
SART3 and Lsm8 siRNA both reduced U6 snRNA binding, and
Lsm2 completely abrogated it. Importantly, none of the deple-
tions affected the abundance of U6 or U4 snRNAs (Figure 3C).
Pat1b thus co-immunoprecipitates SART3 via Lsm2, Lsm8,
and U6 snRNA, linking Pat1b/Lsm2-8/U6 snRNA/SART3, as
RNase treatment prevents this interaction (Figure 2), as do de-
pletions of Lsm2 and Lsm8, but not Lsm1 (Figure 3). Moreover,
the T522E mutation in Pat1b abrogates binding to Lsm8,
SART3, and U6 snRNA, without altering the Lsm1 association
(Figure 2).
These observations prompted us to examine the distribution
and interactions of Pat1b and Lsm proteins in nuclei and the
cytoplasm. Biochemical fractionation of HEK293 cells wasmoni-
tored by western blotting using antibodies to ribosomal protein
S6 and nuclear lamin A/C (Figure S5A). Endogenous Pat1b
was present in both the cytoplasmic and nuclear fractions of un-
treated cells, consistent with our previous study (Marnef et al.,
2012). We estimate that a significant pool of endogenous
Pat1b (20%) at steady state is nuclear. Interestingly, Pat1b
mobility was lower in the nucleus, suggesting that nuclear
Pat1b is a modified (possibly phosphorylated) relative of the
cytoplasmic form.
We then interrogated the effects of the Pat1b T522E mutation
on Lsm interactions in nuclear and cytoplasmic fractions.
Following transfection of HEK293 cells with FLAG-Pat1b or
FLAG-GFP, lysates were fractionated into nuclear and cyto-
plasmic pools as above, and these were then subjected to
FLAG antibody precipitation (Figure S5B). As expected, Lsm1
is cytoplasmic, while Lsm2 partitions across both fractions.
Pat1b/Lsm1 binding was unaffected by the mutation, as in totalCell Reports 20, 1187–1200, August 1, 2017 1191
Figure 3. Interactions Linking Pat1b/Lsm2-
8/U6 snRNA/SART3
(A) FLAG-GFP and FLAG-Pat1b plasmids were
transiently transfected into HEK293 cells co-ex-
pressing control (b-globin) and specified siRNAs.
Lysates were analyzed by western blotting as in
Figure 2.
(B) U6 and U1 snRNA bound by immunoprecipi-
tated proteins was analyzed by qRT-PCR, as in
Figure 2. Average and SD values for technical du-
plicates and error bars are shown.
(C) snRNA levels are largely unaffected by SART3
or Lsm protein knockdown, as determined by qRT-
PCR, using input samples from (B). U4/U6 snRNA
levels were normalized to U1 snRNA. Average and
SD values of three biological replicate experiments
are shown.
(D) FLAG-GFP and FLAG-SART3 plasmids were
transfected into HEK293 cells along with control
(b-globin) and Pat1b siRNAs. Lysates were
analyzed by western blotting.
(E) U6 and U1 snRNA bound by immunoprecipi-
tated proteins was analyzed by qRT-PCR. Average
and SD values for technical duplicates and error
bars are shown.
See also Figure S5.lysates (Figure 2). However, the interaction with Lsm2 was pref-
erentially affected by the nuclear mutant protein, rather than the
cytoplasmic one (Figure S5B), explaining its partial reduction in
total lysates (Figure 2). Of note, as shown by fractionation (Fig-
ure S5B) and immunofluorescence (Figure 4B), the T-E mutation
does not alter the cytoplasmic/nuclear distribution of Pat1b.
Thus there are two compartmentalized Pat1b-Lsm com-
plexes, the cytoplasmic Pat1b/Lsm1-7 and the nuclear Pat1b/
Lsm2-8. Moreover, nuclear Pat1b, via Lsm2-8, interacts with
U6 snRNA and SART3.
Pat1b Stabilizes SART3-Lsm2/8 Interactions
To understand the possible role of Pat1b interactions with
Lsm2-8 and SART3, we depleted Pat1b in cells transfected
with FLAG-SART3 or FLAG-GFP. Following immunoprecipita-
tion, western blotting showed loss of binding of Lsm2 and1192 Cell Reports 20, 1187–1200, August 1, 2017Lsm8 to SART3 when Pat1b levels were
reduced, although SART3-Prp31 interac-
tions were less affected (Figure 3D). In
contrast, SART3-U6 snRNA binding was
unaltered in Pat1b-depleted cells (Fig-
ure 3E). Co-precipitation of U6 snRNA
by SART3 uncomplexed with Lsm2-8 is
in line with in vitro data (Bell et al., 2002).
Together, these data suggest that Pat1b
enhances or stabilizes interactions be-
tween SART3 and Lsm2-8.
Pat1b Co-localizes with SART3 and
Coilin in Cajal Bodies
WenextmonitoredPat1b cellular distribu-
tion by immunofluorescence, first usingthe NES mutant form of GFP-Pat1b (Figure 4A; Marnef et al.,
2012). In addition to diffuse nucleoplasmic localization, Pat1b-
NES concentrated in small foci with coilin, one of the main Cajal
body components, as well as with SART3, which is also enriched
in Cajal bodies (Stanĕk et al., 2003). These non-membrane nu-
clear compartments are involved in aspects of short non-coding
RNA metabolism, including snRNP biogenesis (reviewed in
Stanek, 2016). Interestingly, the T-E mutation reduced Pat1b
co-localization with coilin (from 71% to 12%) and SART3 (from
82% to 29%) (Figure 4A), in linewith the severing of the co-immu-
noprecipitation with SART3 and U6 snRNA (Figures 2 and 3).
Wild-type Pat1b, whether endogenous or GFP tagged, is
concentrated in cytoplasmic P bodies (Figure 4B; Braun et al.,
2010; Marnef et al., 2010; Ozgur et al., 2010). Strikingly, the
T-E mutation here not only prevented GFP-Pat1b from localizing
to P-bodies but also was dominant negative for endogenous
Figure 4. Pat1b Co-localizes with Coilin and SART3 in
Cajal Bodies
(A) HeLa cells were transiently transfected with GFP-Pat1b-
NES plasmids, co-stained with SART3 or coilin antibodies (Cajal
body markers), and processed for immunofluorescence. The
frequency of Pat1b co-localization with Cajal bodies is indicated
(in percentage: average and SD from three independent experi-
ments). Scale bars, 10 mm.
(B) HeLa cells were transfected with GFP-Pat1b plasmids, co-
stained with DDX6 antibodies (P-body marker), and processed
for immunofluorescence. DAPI staining was used to label nuclei.
Scale bars, 10 mm.
(C) Graph showing the number of endogenous P bodies per cell,
detected by DDX6 antibodies, in cells expressing indicated GFP-
tagged plasmids. Average and SD values from four independent
experiments are shown. The significance was assessed by the
two tailed t test (ns, p > 0.05; ***p < 0.001; ****p < 0.0001).
See also Figure S6.
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P bodies (Figures 4B and 4C), presumably reflecting changes in
interacting protein association. Indeed, the NES form of Pat1b
also reduces the number of P bodies per cell (Figure 4B, C), sug-
gesting the possible co-redistribution of some of these factors to
nuclei or abortive complexes formed by a key P-body factor
trapped by the cytosolic mutant protein.
To further examine the possible interdependence of Cajal
bodies and P bodies on Pat1b or Lsm proteins, we induced their
knockdown by RNAi and used coilin and DDX6 antibodies to
quantitate the number and size of the nuclear and cytoplasmic
foci (Figures S6A and S6D). Cajal bodies were not significantly
affected by Pat1b or Lsm1 depletion but were considerably
enlarged both in size and number in the absence of Lsm2 or
Lsm8 (Figure S6C). Such an increase may reflect the accumula-
tion in Cajal bodies of di-snRNP stalled at the recycling step (No-
votny´ et al., 2015; Schaffert et al., 2004). Pat1b, Lsm1, and Lsm2
depletion reduces P-body number, as reported previously for
Pat1b and Lsm1 (see Introduction; Eulalio et al., 2007). In striking
contrast, loss of Lsm8 very clearly enhances P bodies (Fig-
ure S6B). Indeed, as shown by Novotny et al. (2012), Lsm8
depletion results in nuclear Lsm4 being redistributed to the cyto-
plasm, leading to enhanced P-body formation. We conclude that
the dynamic connection between these nuclear and cytoplasmic
foci is particularly susceptible to the balance and distribution of
nuclear and cytoplasmic Lsm proteins.
Pat1b Depletion Stabilizes mRNAs Normally Found in
P Bodies
To assess the role of Pat1b in P-body- and snRNP-related pro-
cesses, namely mRNA decay and splicing, the transcriptome
of Pat1b and control-siRNA-treated HEK293 cells was analyzed
by RNA sequencing (RNA-seq). Two biological replicates were
analyzed, resulting in highly consistent data with pairwise Pear-
son correlations of >0.99 (Figures S7A and S7B). High-confi-
dence changes (p < 0.05) in 3,703 transcript levels were
observed, 60% of which were upregulated following Pat1b
knockdown, in line with its role in mRNA decay (Figures 5A and
5B). GO analysis of this class revealed the enrichment of mRNAs
involved in RNAmetabolic processes and RNA-binding function,
including small non-coding RNA and biogenesis, ribosome
biogenesis, splicing, translation, mRNA decay, and other RNA-
binding proteins. In contrast, the transcripts whose levels
decreased upon Pat1b knockdown encoded proteins involved
in developmental processes (Figures S7C and S7D).
Recently, P bodies were purified in HEK293 cells and their
RNA content identified. A large variety of RNAs are specifically
stored in P bodies, while others are excluded (A. Hubstenberger,
M. Courel, M. Be´nard, S., Souque`re, M. Ernoult-Lange,
R. Chouaib, Z. Yi, J.-B. Morlot, A. Munier, M. Fradet, M. Dau-
nesse, M. Bertrand, G. Pierron, J. Mozziconacci, M. Kress,
D.W., unpublished data). Interestingly, we found that RNA stabi-
lization after Pat1b silencing correlated positively with enrich-
ment in P bodies (correlation coefficient, 0.39) (Figure 5C).
Indeed, 80% of the RNAs that were significantly stabilized
were also significantly enriched in P bodies, compared to only
17% of the RNAs that were significantly downregulated (Fig-
ure 5C). Pat1b is a component of P bodies, and its depletion
reduces their number (Figure S6; Ayache et al., 2015; Marnef1194 Cell Reports 20, 1187–1200, August 1, 2017et al., 2010; Ozgur et al., 2010). Hence Pat1b-dependent decay
preferentially affects RNAs that are normally stored in P bodies.
Since AU-rich elements (AREs) are well-known determinants
of mRNA degradation, we analyzed their frequency in Pat1b-
sensitive mRNAs using the ARED database (Halees et al.,
2008). ARE-containing mRNAs were much more frequent in up-
regulated mRNAs than in downregulated mRNAs, rising to 29%
for the most significantly increased compared to less than 10%
for downregulated ones (Figure 5D). The mRNA targets of two
ARE-binding proteins, TTP and HuR, have been characterized
by cross linking immunoprecipitation (CLIP) in HEK293 cells (Mu-
kherjee et al., 2011; Mukherjee et al., 2014). Their link with Pat1b
upregulation was even stronger than that of AREs. Up to 31% of
the most significantly upregulated mRNAs were TTP targets,
compared to less than 5% of the downregulated ones (Fig-
ure 5D). Similarly, up to 53% of the upregulated mRNAs were
HuR targets, compared to less than 8% of the downregulated
ones (Figure 5D). Thus, Pat1b-dependent decay preferentially
affects ARE-containing mRNAs as well as TTP and HuR targets.
Searching for any factor related to downregulation after Pat1b
silencing, we found that SMN-bound mRNAs (Rage et al., 2013)
were twicemore frequent in significantly down regulatedmRNAs
than in upregulated mRNAs (Figure 5D). This Pat1b-SMN link is
probably even more significant, as SMN-bound mRNAs were
characterized in the distant murine motor neuron-like NSC34
cell line. Although the exact function of SMN on these RNAs
remains to be determined, it raises the possibility that Pat1b sta-
bilizes, directly or indirectly, SMN targets.
Pat1b Promotes Inclusion of Cassette Exons
Next, we examined the potential role of Pat1b in regulating alter-
native splicing. Significant changes in splicing were predicted
by rMATs. This identified 189 alternative splicing events (ASEs),
withmore than80%at the level of inclusionor skippingof cassette
exons (CEs). Of the regulatedCEs, 85%showeddecreased inclu-
sion upon Pat1b depletion, suggesting that Pat1b normally pro-
motes their inclusion (Figure 6A). We validated a number of these
predicted ASEs, including examples of activated and repressed
cassette exons (ACEs and RCEs), and alternative 30 or 50 splice
sites. RT-PCR was performed using primers in flanking constitu-
tive exons, and the percentage exon inclusion was determined
(Figure 6B). These outcomes are unlikely to result from off-target
effects of Pat1b RNAi, as similar results were noted for the three
ACE transcripts in cells depleted of SART3, or Lsm 2 or Lsm8,
with Lsm2/8 knockdowns showing the greatest effects. Signifi-
cantly, Lsm1 depletion did not influence their alternative splicing,
and none of the depletions changed snRNA levels (Figure 6C-E).
To assess whether the exons regulated by Pat1b possess any
specific splicing features they were compared to a control set
of 16228 CEs that were insensitive to Pat1b depletion (Figure 7).
While ACEs tended to be modestly but significantly shorter than
control exons, their flanking introns were strikingly shorter (by a
median of 1,030 nt compared to 2,337 nt for the control), with
higher GC content (by a median of 46% versus 41% for the con-
trol for upstream intron and 44%versus 41% for the downstream
intron) (Figures 7A–7C). We then analyzed the strength of the
different splice sites. As expected, the regulated cassette exons
have weaker donor and acceptor splice sites compared to the
Figure 5. RNA-Seq Analysis of Transcrip-
tome Changes following Pat1b Knockdown
in HEK293 Cells
(A) Volcano plot representing log2 fold changes
in RNA expression and their associated p values.
Differential gene expression was analyzed using
DESeq2.
(B) Pie chart showing the number of high-confi-
dence (p value < 0.05) upregulated (in red, fold
change > 0) or downregulated (in blue, fold
change < 0) transcripts after Pat1b depletion.
(C) Positive correlation between upregulation after
Pat1b depletion and enrichment in P bodies. The
dot plot represents the 16,451 RNAs common to
both analyses, while the pie chart shows the strong
overlap between transcripts significantly upregu-
lated after Pat1b depletion (in red) and significantly
enriched in P bodies (in black).
(D) Enrichment of AU-rich element (ARE) mRNAs
and targets of TTP and HuR in upregulated RNAs,
and enrichment of SMN targets in downregulated
RNAs. For each panel, the bars represent the
percentage of transcripts of interest in the RNAs
that are up- or downregulated after Pat1b deple-
tion, while the tag above the bars is their absolute
number. The total number of RNA targets in the
Pat1b dataset is indicated. The enrichment is
stronger for highly confident fold changes.
See also Figure S7.constitutive exons in the control set. The 50 splice sites (Fig-
ure 7D, Ds Dn) of the ACEs were significantly weaker than those
of the control CEs, whereas the 30 splice site of the constitutive
exon (Ds Ac) were slightly but significantly stronger (Figure 7E).
Altogether, these data indicate that Pat1b enhances the inclu-
sion of cassette exons that have significantly weaker donor
and acceptor sites than their flanking constitutive exons and
that are flanked by short introns.
DISCUSSION
Two Pat1-Lsm Complexes
This study reports that Pat1b, in addition to its well-known inter-
actions with the cytoplasmic Lsm1-7 heptamer, also associatesCell Rewith its nuclear Lsm2-8 counterpart.
The X-ray crystal structure of the yeast
Pat1C /Lsm1-7 complex was recently
solved and shown to be bridged by
Lsm2 and Lsm3 interactions (Sharif and
Conti, 2013; Wu et al., 2014), consistent
with a nuclear Pat1b/Lsm2-8 complex.
Indeed, modeling of the yeast Lsm2-8
heptamer (Zhou et al., 2014) onto the
PatC domain (Sharif and Conti, 2013) re-
vealed considerable overlap between the
two rings and compatibility of PatC with
Lsm2-8 interactions (Figure S1). The nu-
clear Pat1/Lsm complex is likely to be
conserved, as Drosophila HPat can accu-
mulate in nuclei (Pradhan et al., 2012), andfungal Pat1 shuttles through nuclei in Saccharomyces cerevisia
(S. c.) (Teixeira and Parker, 2007) and Schizosaccharomyces
pombe (S. p.) (Wang et al., 2017).
Interestingly, changing Pat1b T522 to glutamic acid differen-
tially impacts its binding to Lsm8 and Lsm1. This mutation,
located close to the Lsm2/3-Pat1b interface, introduces
a possible phosphomimetic residue in a predicted PKA
consensus site, KRRKT522LVI, which lies in a very similar loca-
tion to the yeast Pat1p PKA site, RRRS456S457Y (Ramachan-
dran et al., 2011). Similarly to the outcome of this phosphory-
lation in yeast Pat1p, the T522E mutation was dominant
negative for endogenous P bodies. Also of note, nuclear
Pat1b appears to be modified relative to its cytoplasmic form.
We speculate that the difference of Pat1b/Lsm complexes inports 20, 1187–1200, August 1, 2017 1195
Figure 6. Splicing Regulation Mediated by
Pat1b
(A) Schematic representation of the different cat-
egories of alternative splicing and the summary of
splicing changes following Pat1b depletion, re-
vealed by RNA-seq analysis with rMATS pipeline.
The first pie chart shows the number of events
affected by Pat1b depletion in each category.
Among regulated cassette exons, a second pie
chart shows the distribution between activated
and repressed CEs.
(B) Validation of splicing events with RT-PCR.
Values shown are mean ± SD of the PSI (percent
spliced in) (n = 3).
(C) HEK293 cells were treated with control
(b-globin); Pat1b; SART3; Lsm1, 2, and 8 siRNA;
and PSI for three ACE splicing events were as-
sessed by RT-PCR. Mean ± SD values are shown
(n = 3).
(D) U4/U6 and U1 snRNA levels were determined
by qRT-PCR.
(E) Western blot verification of siRNA knockdown
with indicated antibodies.the cytoplasm and nuclei, whether due to different Pat1b
conformation or distinct co-factors, possibly results from differ-
ential phosphorylation.1196 Cell Reports 20, 1187–1200, August 1, 2017How Pat1b binds RNA is also of inter-
est in regard to how it functions, partic-
ularly as it lacks any known RNA-bind-
ing domains or motifs. Pat1 proteins
have been shown to bind mRNA via
the Lsm1-7 complex as well as in an
Lsm-independent manner (Braun et al.,
2010; Chowdhury et al., 2014; Chowd-
hury et al., 2007; Haas et al., 2010;
Mitchell et al., 2013; Pilkington and
Parker, 2008). However, detailed under-
standing of these interactions is still
lacking. This study, which shows that
Pat1b can also bind Lsm2-8 and in
turn U6 snRNA, widens the scope
for future investigations of Pat1-RNA
interactions.
The Pat1b/Tri-snRNP Connection
The extended interactions linking Pat1b/
Lsm2-8 to U6 snRNA and in turn SART3
were demonstrated using mass spec-
trometry, immunoprecipitation coupled
with northern and western blotting, and
RNAi depletion. The well-established
binding of Lsm2-8 to U6 snRNA as well
as now to Pat1b is compatible with struc-
tural studies. The U-rich 30 end of U6
snRNA binds the inner core of the hep-
tamer ring (Zhou et al., 2014), with the
PatC domain interacting with the out-
ward-facing residues of Lsm2-3 subunits(Figure S1; Sharif and Conti, 2013; Wu et al., 2014). Furthermore,
Prp24/SART3 binds the telestem region of U6 snRNA and Lsm2-
8 to its 30 end (Montemayor et al., 2014). Altogether, these
Figure 7. Properties of Pat1b-Regulated Cassette Exons
(A) Length distribution of Pat1b-regulated exons.
(B) Length distribution of introns (upstream and downstream).
(C) Intron GC content (percentage).
(D) Schematic cartoon of features of activated cassette exons regulated by
Pat1b. Up, upstream; Ds, downstream; Dn, donor; Ac, acceptor.
(E) Splice site strength (maximum entropy). A two-sided Mann-Whitney test
was used to compare properties between datasets (ns, p > 0.05; *p < 0.05;
**p < 0.01; ***p < 0.001; ****p < 0.0001).observations suggest that Pat1b participates in some aspect of
tri-snRNP biogenesis, as this is the well-established role of
SART3, which re-anneals U4 and U6 snRNA, and of Lsm2-8
(Bell et al., 2002; Verdone et al., 2004). The interaction of Pat1b
with SART3 and U5 proteins suggests that Pat1b may interact
with all snRNPs containing the Lsm2-8 ring (U6, U4/U6, and
U4/U6.U5 snRNPs).
We also documented the specific additional binding of tri-
snRNP proteins to Pat1b, albeit with a mode of binding distinctfrom SART3. In the case of Prp31, its binding to Pat1b was
RNA and Lsm independent and only mediated by the PatC
domain. The other tri-snRNP proteins could not be explored in
any great detail, largely owing to lack of antibodies. However,
a recent proteomic analysis of column-based fractionations of
nuclear and cytoplasmic HeLa and HEK293 cell proteins identi-
fied several hundred soluble complexes (Havugimana et al.,
2012). Interestingly, one of the largest complexes (618) includes
Pat1b and tri-snRNP components (Prp31, Prp3, Prp4, Prp6,
Prp8, and Sm) and additional splicing proteins, but not SART3,
which is consistent with the nuclease treatment used to solubi-
lize protein complexes (Havugimana et al., 2012). Interestingly
too, yeast Pat1p was previously detected in U6-containing
penta-snRNP (Stevens et al., 2002).
Dual RNA-Processing Functions of Pat1b
High-throughput RNA-seq following Pat1b silencing showed
changes in both transcript levels and alternative splicing, which
affected different sets of genes. Pat1 proteins may have addi-
tional roles in regulating gene expression. In S. cerevisiae, with
relatively low levels of splicing and alternative splicing (AS)
restricted to regulated intron retention (Pleiss et al., 2007), dele-
tion of Lsm2-5 and 8 or Pat1p results in delayed rRNA process-
ing (Kufel et al., 2003; Muppavarapu et al., 2016). Our RNA-seq
data lack information on rRNA species, as the RNA was sub-
jected to RiboZero treatment. Nevertheless, ourmass spectrom-
etry data, documenting multiple interactions with mRNA decay
machinery and tri-snRNP components, do not support a major
role for human Pat1b in rRNA processing.
The mRNAs normally destabilized by Pat1b include many
with functions in RNA metabolism and RNA binding, in
line with idea that RNA binding proteins (RBPs) are part of
cross-regulatory post-transcriptional networks, the ‘‘regulator-
of-regulator’’ concept (reviewed Iadevaia and Gerber, 2015).
Less anticipated was our observation that the upregulated tran-
scripts showed a significant correlation with mRNAs purified
from P bodies in untreated cells and with ARE mRNAs. Taking
into account the previous model that P bodies could sequester
untranslated ARE-containing mRNAs upstream of their decay
(Franks and Lykke-Andersen, 2007), these data altogether sug-
gest that Pat1b is specifically involved in this decay pathway.
We noted a relatively modest number of AS changes when
Pat1b was depleted, possibly reflecting the minor proportion
of nuclear Pat1b in proliferating HEK293 cells. As judged by
the low frequency of intron retention events, Pat1b knockdown
does not affect global splicing efficiency. Rather, Pat1b tends
to enhance the inclusion of shorter than usual exons, with
particularly weak splice sites compared to their adjacent
constitutive exons. Weaker splice sites are usually thought to
affect initial recruitment of early splicing factors, including
U2AF, U1, and U2 snRNPs. We suggest that Pat1b nor-
mally enhances a step in tri-snRNP assembly by stabilizing
SART3/Lsm2-8 interactions, without affecting snRNA levels.
When tri-snRNPs are abundant, those exons are included,
despite their weaker splice sites, possibly because the weak
binding of earlier factors is rapidly stabilized by subsequent
binding of tri-snRNP. However, when Pat1b is silenced, tri-
snRNP is reduced and its inclusion is less efficient. ConsistentCell Reports 20, 1187–1200, August 1, 2017 1197
with this possibility, we note that Pat1b-regulated exons are
flanked by considerably shorter than usual introns, which would
be transcribed faster than normal, leading to reduced recogni-
tion of weak splice sites when tri-snRNP levels are suboptimal.
Indeed, cassette exons sensitive to the rate of transcription
elongation have shorter flanking introns and weaker splice sites
(Fong et al., 2014). It could seem paradoxical that a decrease in
tri-snRNPs, which are required for all splicing events, only af-
fects AS. However, a high-throughput siRNA screen of core
and auxiliary regulatory splicing factors, including a number
of tri-snRNP components, revealed that their depletion, rather
than resulting in a general uniform inhibition of splicing, induced
differential effects upon >35 functionally important AS events
(Papasaikas et al., 2015). We propose therefore that Pat1b,
which by virtue of its interactions with tri-snRNP likely acts
late in the splicing complex assembly, can nevertheless affect
splice site choice. Further support for this model comes from
a recent kinetic study that showed that all steps in spliceosome
assembly up to and including U4/6.U5 tri-snRNP recruitment
are reversible and thus potential points of regulation (Hoskins
et al., 2016).
In summary, this work identifies the dual pre/mRNA process-
ing roles of Pat1b, an RNA-binding protein that is mostly cyto-
plasmic in mammalian tissue culture cells but shuttles in and
out of nuclei and is a component of both P bodies and Cajal
bodies. We speculate that the cellular distribution of Pat1b
may differ in other cell types, likely altering the balance of its
effects on gene expression.
EXPERIMENTAL PROCEDURES
Additional methods are detailed in Supplemental Experimental Procedures.
Mass Spectrometry
HEK293cellswere transiently transfectedwitheither FLAG-Pat1borFLAG-GFP
plasmids 24 hr after plating. After a further 24 hr, cells were harvested and the
tagged proteins purified with anti-M2 affinity gel (Sigma). Bound proteins were
eluted using FLAGpeptide (Sigma) and separated briefly by SDS-PAGE, as pre-
viously described for FLAG-4E-T (Kamenska et al., 2016). Each lane was sliced
into four slices, and tryptic peptides obtained by in-gel digestion were identified
using one-dimesional sodium dodecyl sulfate-polyacrylamide gel electropho-
resis followed by liquid chromatography-tandem mass spectrometry (GELC/
MS/MS) in the Cambridge Centre for Proteomics. Peptide analysis was carried
out with Proteome Discoverer using the SwissProt database.
Immunoprecipitation, Western Blot Analysis, and qRT-PCR
Immunoprecipitation of FLAG-tagged proteins was performed with lysates
from transfected cells incubated with M2 beads (Sigma Aldrich), and after
washing, bound proteins and RNA were eluted and analyzed by western blot-
ting or qRT-PCR (see Supplemental Experimental Procedures).
HeLa Cell Culture, Transfection, and Immunofluorescence
HeLa cells were maintained in DMEM supplemented with 10% fetal bovine
serum. Transient transfections were performed as described above with cells
plated on 13-mm glass coverslips in 24-well plates. Cells were fixed in 4%
paraformaldehyde, washed with PBS, and permeabilized in PBS with 0.5%
Triton X-100 followed by PBS washes. Cells were incubated with primary an-
tibodies for 1 hr. The cells were washed in PBS, followed by the incubation of
the secondary antibodies conjugated to rhodamine or Alexa 488 used at a
1:1,000 dilution (Jackson ImmunoResearch Laboratories) for 1 hr. After rinsing
three times with PBS, cells were stained with DAPI. The coverslips were
mounted in Citifluor medium (Citifluor). All steps were performed at room tem-1198 Cell Reports 20, 1187–1200, August 1, 2017perature. Cells were observed under a Zeiss Axioimager M1 fluorescence
microscope.
RNA-Seq
RNA from two biological replicates each of b-globin or Pat1b siRNA-treated
HEK293 cells was extracted with TriReagent and analyzed in the DNA
sequencing facility of the Department of Biochemistry (University of Cam-
bridge). Ribo-Zero TruSeq stranded mRNA libraries were prepared for each
sample and sequenced on Illumina NextSeq 500 Sequencing System
providing around 100 million reads per sample (75-bp paired-end reads).
See Supplemental Experimental Procedures for details regarding RNA-seq
analysis.
Statistical Methods
The number of P bodies per cell and co-localization of GFP-Pat1b proteins
with coilin/SART3 in Cajal bodies were quantitated in 50 cells in three or
four independent experiments, respectively, using ImageJ. The significance
was assayed by two-tailed t test (not significant [ns], p > 0.05; ***p < 0.001;
****p < 0.0001).
The two-sidedMann-Whitney test was used to compare properties between
regulated cassette exon datasets (ns, p > 0.05; *p < 0.05; **p < 0.01; ***p <
0.001; ****p < 0.0001). All statistical analyses were performed with RStudio.
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